{
    "Trade/Device Name(s)": [
        "DreaMed Advisor Pro"
    ],
    "Submitter Information": "DreaMed Diabetes Ltd",
    "510(k) Number": "K201476",
    "Predicate Device Reference 510(k) Number(s)": [
        "K191370"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "QCC"
    ],
    "Summary Letter Date": "August 28, 2020",
    "Summary Letter Received Date": "June 3, 2020",
    "Submission Date": "June 3, 2020",
    "Regulation Number(s)": [
        "21 CFR 862.1358"
    ],
    "Regulation Name(s)": [
        "Insulin therapy adjustment device"
    ],
    "Analyte Class(es)": [
        "chemistry",
        "endocrine"
    ],
    "Analyte(s)": [
        "Glucose"
    ],
    "Specimen Type(s)": [],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "Insulin pump",
        "Continuous Glucose Monitoring (CGM) system",
        "Self-Monitoring Blood Glucose (SMBG) meter",
        "Diabetes Management System (DMS)"
    ],
    "Method(s)/Technology(ies)": [
        "Software analysis"
    ],
    "Methodologies": [
        "Decision-support recommendation software"
    ],
    "Submission Type(s)": [
        "Software"
    ],
    "Document Summary": "FDA 510(k) summary for DreaMed Advisor Pro decision-support software for insulin therapy adjustments in type 1 diabetes patients using insulin pumps and CGM/SMBG data.",
    "Indications for Use Summary": "Assists healthcare professionals in managing type 1 diabetes patients (age 6+) on insulin pumps, using CGM and/or SMBG, by generating recommendations for insulin pump settings optimization; not a replacement for clinical judgement.",
    "fda_folder": "Clinical Chemistry"
}